The first medication approved by FDA as part of an expedited generic drug program is one that has been in short supply.
FDA okayed iobenguane I 131 (Azedra, Progenics Pharmaceuticals) injection for IV use to treat rare tumors of the adrenal gland.
Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.
FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.
A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.
FDA approved a novel device to treat breathing difficulty associated with severe emphysema.
A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.
FDA’s approval of a cannabidiol (CBD) medicine to treat seizures associated with 2 severe forms of epilepsy is a positive sign for other CBD drugs under development.
The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.
FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.